Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.56 |
| ▸ | THRA | P10827 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.53 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4304889 | 0.97 | PPARG (0.55) | PPARGPPARATHRATHRBCYSLTR2 | |
| SCHEMBL7290141 | 0.91 | KDM4E (0.51) | PPARGPPARAHDAC3HDAC1HDAC2 | |
| SCHEMBL2448097 | 0.90 | PTPN11 (0.61) | CYSLTR2CYSLTR1TP53TSHRPTPN11 | |
| SCHEMBL5492191 | 0.89 | PTPN11 (0.64) | THRATHRBTP53TSHRPTPN11 | |
| SCHEMBL7820620 | 0.89 | PTPN11 (0.64) | THRATHRBTP53TSHRPTPN11 | |
| SCHEMBL11237589 | 0.88 | THRA (0.67) | PPARGPPARATHRATHRBTP53 | |
| SCHEMBL12432167 | 0.88 | THRA (0.67) | PPARGPPARATHRATHRBTP53 | |
| SCHEMBL9525503 | 0.88 | LMNA (0.54) | THRATHRBCYSLTR2CYSLTR1HDAC3 | |
| SCHEMBL1750042 | 0.87 | PTPN11 (0.57) | PPARGPPARATHRATHRBTP53 | |
| SCHEMBL4304885 | 0.87 | HDAC3 (0.54) | THRATHRBCYSLTR2CYSLTR1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022072-B2 | Azolylmethylidenehydrazine derivative and use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2168951-A1 | AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-20090069430-A1 | DIBENZENE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROPHARMA, S.A. (ES) | 2009-03-12 | — | — | US | disclosed |
| US-20090069430-A1 | DIBENZENE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROPHARMA, S.A. (ES) | 2009-03-12 | — | — | US | disclosed |
| US-20090069430-A1 | DIBENZENE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROPHARMA, S.A. (ES) | 2009-03-12 | — | — | US | disclosed |
| EP-1976823-A1 | DIBENZENE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuropharma, S.A. (ES) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007068754-A1 | DIBENZENE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROPHARMA, S.A. (ES) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007068754-A1 | DIBENZENE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROPHARMA, S.A. (ES) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069430-A1 | DIBENZENE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNB1, CACNA1C | PPARG 2459/4885PPARA 2017/4885THRA 2702/4885 |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | ARSA, AHR, HRH2 | PPARG 1727/4885PPARA 2247/4885THRA 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.